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Abstract 
Tobacco smoke is a major risk factor for the development of cancers in the upper parts of 
gastrointestinal tract. It has been estimated that the risk of oral cancer among smokers is 
7–10 times higher than for never-smokers.  
Acetaldehyde is formed during the tobacco smoking burning process and may be one 
of the most toxic compounds in tobacco smoke. According to the International Agency for 
Research on Cancer (IARC), in 2004 acetaldehyde was classified as a possible carcinogen 
in humans (Group 2B). In 2009, acetaldehyde was classified in Group 1, as a carcinogen 
to humans. A non-essential-amino acid such as L-cysteine, is able to bind acetaldehyde 
and form 2-methylthiziolidine-4-carboxylic acid (MTCA). 
The general aim of this study was to through formulation studies to explore the ability 
of L-cysteine to eliminate carcinogenic acetaldehyde present in saliva. In addition, the aim 
was to develop user-friendly L-cysteine containing chewing gum to reduce acetaldehyde 
formed during tobacco smoking. The main variables were the chemical form of L-cysteine 
used (L-cysteine or L-cysteine hydrochloride) and the chewing gum preparation method 
(traditional and novel direct compression method). Furthermore, the aim was to obtain 
more information on the optimal formulation properties, using approaches such as stability 
studies and possible interactions between cysteine and used excipients. Caco-2 cell lines 
were used to access the ability of L-cysteine and MTCA to absorb from the 
gastrointestinal tract. A computational model was developed to analyse the effects of 
different physiological factors and effect of formulation parameters on tobacco smoke 
acetaldehyde.  
The combined results of these studies suggested that tobacco smoke carcinogenic 
acetaldehyde can be successfully eliminated with prepared L-cysteine chewing gums. 
Compared to the traditional manufacturing process the directly compressed gum 
formulation can offer an alternative method to traditional chewing gum production. Due to 
the slower dissolution rate, better compatibility with excipients, and better stability under 
higher temperature and humidity, L-cysteine as a free base is a better candidate for 
chewing gum formulation than cysteine hydrochloride.   
The Caco-2 permeability studies indicate no significant risk of the locally administered 
L-cysteine being absorbed before binding to acetaldehyde. Permeability results also 
indicated that MTCA is not absorbed locally from the gastrointestinal tract, which reduces 
the risk of systemic effects. An MTT assay, a widely used cytotoxicity test, demonstrated 
that neither      L-cysteine nor MTCA was toxic to the Caco-2 cells.  
A computational model that was developed was able to show how sensitive 
acetaldehyde is to changes in the amount of L-cysteine as well as in saliva excretion rates. 
The model can be used as a tool for the prediction of drug amount and the local effect in 
the mouth of water-soluble compounds, such as L-cysteine. 
In conclusion, elimination of acetaldehyde, not only carcinogen, but also agent which 
possibly increases the addictive potential of tobacco, might help in the fight against 
smoking and make smoking cessation programs more efficient. L-cysteine, a non-essential 
amino acid, is able to prevent the harmful effects of acetaldehyde by binding acetaldehyde 
and forming MTCA. It should be kept in mind that acetaldehyde elimination does not 
make smoking completely harmless and tobacco smoke contains other carcinogens and 
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addictives. The best way to protect from tobacco induced diseases is to refrain from 
smoking. However, besides the fact that most smokers want to quit but most attempts fail 
and since tobacco smoke contains many carcinogenic compounds, in the future, developed 
computational models can offer a new view in eliminating or reducing not only one toxic 
compound from tobacco smoke but also many other compounds using only one 
formulation containing various active compounds. 
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1 Introduction 
According to the World Health Organisation (WHO, 2007), there are more than one 
milliard tobacco smokers in the world. About 80 % of smokers live in low and middle-
income countries (Jha, 2009). Tobacco use kills 6 million people each year and by 2030 it 
will kill more than 8 million people each year (WHO, 2011). The dangers of smoking are 
well known and despite well documented health consequences of tobacco use, it continues 
to be a public health issue. Thus, there is an urgent need to inform smokers how to reduce 
their tobacco caused health risks, to encourage smokers to quit, to emphasise the 
importance of successful nicotine replacement therapy (NRT) and, most importantly, to 
inform young non-smokers of why they should not start smoking. 
Oral cancer is the seventh most common cancer worldwide and has a poor prognosis.  
The five year survival rate for people diagnosed with late-stage oral cancer is 
approximately 16 % (Cawson and Odell, 2002). One of the main risk factors for the 
develop of oral cancer is tobacco smoking. This can be explained by the high levels of 
acetaldehyde formed during the burning process that may represent one of the most toxic 
compounds in tobacco smoke (Smith and Hansch, 2000; Seeman et al., 2002). According 
to IARC monograph from 2009, acetaldehyde was classified in Group 1, as a carcinogen 
to humans (Secretal et al., 2009). However, it should be mentioned that still in 2004, 
acetaldehyde was listed as a possible carcinogen in humans (Group 2B). Besides its 
carcinogenic properties, some studies have shown that acetaldehyde may increase the 
addictive potential of nicotine.   
A non-essential-amino acid, such as L-cysteine, is able to bind acetaldehyde and form 
2-methylthiazolidine-4-carboxylic acid (MTCA) (Sprince et al., 1974). Thus, high 
acetaldehyde concentrations found in the mouth during smoking can be reduced using L-
cysteine containing products (Salaspuro et al., 2006). Taking into account that L-cysteine 
products are intended to be used by tobacco smokers, a dosage form may be a way to 
achieve good user compliance. To achieve the best possible user compliance, the design of 
a proper formulation is increasingly important. For example, compared to lozenges, 
chewing gum may allow better control of the release rate - since lozenges may be broken 
by biting, which again can result in rapid L-cysteine release from the lozenge.  
In recent years, academic as well as drug development companies have paid more 
attention to the extremely high costs in the drug development process (DiMasi et al., 2003; 
Gobmar, et al. 2003; Vernon et al., 2010). One of the big issues is also the time required to 
get successful medicine to the market: typically a very time-consuming process. More 
effective methods such as computational methods as well as in vitro cell cultures are 
possible options to reduce costs. Computer modelling might be used in drug discovery and 
development from the early beginning to evaluate potential compounds for clinical trials 
(Leahy, 2003). Moreover, the model can be used to select proper drug candidates into 
early preformulation studies and to obtain answers on drug efficacy and safety in different 
patient populations. In the preformulation studies, the mean aim is to develop as safe and 
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efficient a product as possible for further clinical studies. Thus, the main questions are: 
manufacturing process, compatibility studies between active drug and excipients, factors 
affecting drug release, as well as benefits for patients such as formulation functionality, 
efficacy, convenience, and lifestyle.  
Taking into account that over one milliard people smoke, and besides the fact that most 
smokers want to quit but most attempts fail, supportive means to help in fight against 
smoking are needed.  
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2 Review of the literature 
2.1 Health effects of tobacco 
Tobacco use is one of the main risk factors for a number of chronic diseases, including 
cancer, lung diseases, and cardiovascular diseases. Smoking is estimated to be the cause of 
40–45 % of all cancer deaths, 90–95 % of lung cancer deaths, over 85 % of oral cancer 
deaths, 75 % of chronic obstructive lung disease deaths, and 35% of cardiovascular 
disease deaths (Johnson, 2001; Jha, 2009). It is by far the main contributor to lung cancer 
(Biesalski et al., 1998; Johnson et al., 2000), and it is an important cause of at least 15 
different types of cancer in various organs including the oral cavity, oropharynx, 
esophagus, stomach, colon, liver, pancreas, kidney, urinary bladder, and breast (IARC, 
2004).  
The dangers of smoking are well known and despite well documented health 
consequences of tobacco use, it continues to be a public health problem. Efforts are 
needed to prevent and to reduce cancers caused by smoking and thus prevent one-third of 
cancer diseases. In the past decades, Western countries have been restricting tobacco 
advertising, and regulating who can buy and use tobacco products, and where people can 
smoke. In addition, public health organisations campaign openly against tobacco smoking 
emphasizing smoking prevention. Although, according to Gilpin et al. (1999) 
approximately 4800 adolescents (age 11–17 years) and 5500 youths (age 11–20 years) 
experiment with cigarettes for the first time each day, and up to almost 42 % of them 
develop smoking addiction. Whilst most smokers from industrialised countries would 
agree that their habit is dangerous, and the majority would want to quit, they often fail. 
Even after stopping, most relapse within 12 months, which is attributable to nicotine 
dependence (Croghan et al., 2003). The reasons for tobacco smoking addiction can be 
found not only in biochemical addition but also in social behaviour. Acetaldehyde’s role 
in smoking addiction will be discussed more in section 2.3. 
Tobacco smoke contains more than 4000 components, the main ones being nicotine, 
tar and carbon monoxide. From those 4000 components at least 69 are identified 
carcinogens in humans and/or animals (IARC, 2004). Carcinogens are divided into three 
groups according to their carcinogenicity. Of the 69, 11 belong to Group 1 and they are 
known as human carcinogens, 7 from Group 2A are probably carcinogenic in humans, and 
49 from Group 2B of animal carcinogens are possibly also carcinogenic to humans. They 
belong to various classes of chemicals, as follows: polycyclic aromatic hydrocarbons 
(PAH) (10 compounds), N-nitrosamines (10), miscellaneous organic compounds (10), and 
metals and other inorganic compounds (9), heterocyclic amines (7), heterocyclic 
compounds (6), aromatic amines (4), volatile hydrocarbons (4), nitro compounds (3), 
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aldehydes (2), and other agents (6). Table 1 lists some of a total of 69 carcinogen agents in 
tobacco smoke and groups of agents.  
It should be noted that levels of the compounds in tobacco smoke are playing an 
important role in their ability to induce tumours in laboratory animals (Pfeifer et. al., 
2002). For example, the concentration of acetaldehyde in tobacco smoke is more than 
1000 times greater than that of PAHs and N-nitrosamines (Hoffmann et al., 2001). 
According to IARC monograph from 2004, acetaldehyde was classified as possible 
carcinogen in humans (Group 2B). In the late 2009, acetaldehyde was classified in Group 
1, as a carcinogen to humans (Secretal et al., 2009). This new classification, highlights the 
importance of reducing carcinogenic acetaldehyde from tobacco smoke.  
 
Table 1. Some of a total 69 carcinogen agents in tobacco smoke and groups of agents 
(IARC, 2004; Secretan et al., 2009). 
 
Agent Group 
PAH  
Benzanthracene 2A 
Benzopyrene 2A 
Dibenzopyrene 2B 
5-Methylchrysene 2B 
N-nitrosamines  
N-Nitrosopyrrolidine 2B 
N-Nitrosopiperidine 2B 
Miscellaneous organic compounds  
Vinyl chloride 1 
Acetamide 2B 
Metals and other inorganic   compounds      
Arsenic 1 
Cadmium 1 
Nickel 1 
Heterocyclic compounds  
Furan 2B 
Benzofuran 2B 
Aromatic amines  
4-Aminobiphenyl 1 
2-Toluidine 2B 
Volatile hydrocarbons  
Benzene 1 
1,3-Butadiene 2B 
Aldehydes  
Acetaldehyde  1 
Other agents  
Nitrobenzene 2B 
2-Nitropropane 2B 
Group 1: Human carcinogens 
Group 2A: Probably carcinogenic to humans 
Group 2B: Possibly carcinogenic to humans 
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2.2 Oral cancer 
 
Epidemiology 
 
Oral cancer is one of the most common cancers in the world, with approximately 270 000 
new cases and 120 500 deaths occurring each year (Parkin et al., 2005). More than 90 % 
of oral cancers are squamous cell carcinomas (SCC). Carcinomas of the oral cavity 
include cancers of tongue, tonsils, salivary glands, as well as the lips, the palate, and the 
cheek. For both genders, oral cancer ranks sixth overall in the world, behind lung, 
stomach, breast, colon and rectum, and cervix plus corpus uteri (Johnson, 2001). In 
industrialised countries, men are affected two to three times as often as women, and the 
reason for that may be attributed to their higher use of alcohol and tobacco. The incidence 
of oral cancer also shows geographical variation and incidence increase with age in all 
countries. 98 % of all patients are over the age of 40. The highest incidence rates for oral 
cancer are found in the South and Southeast Asia, especially in Sri Lanka, India, Pakistan 
and Taiwan, in Brazil, and in Central Europe ranking France, Hungary, and Czech 
Republic very high (Johnson, 2001; Nair et al., 2004). In addition, race is named as a risk 
factor (Silverman, 2001); where African people experience oral cancer twice as often as 
cases reported in the Caucasian population.  
 
Aetiology 
 
As mentioned, tobacco smoke is a major risk factor for the development of cancers in the 
oral cavity and the pharynx (Blot et al., 1988; La Vecchia et al., 1997). It has been 
estimated that the risk of oral cancer among smokers is 7–10 times higher than for never-
smokers (Warnakulasuriya et al., 2005). The risk increases with amount and duration of 
smoking. In a large population-based case control study, Blot et al. (2008) reported that 
those who were both heavy alcohol drinkers and heavy smokers have 38 times more risk 
of oral and pharyngeal cancer than those of non-smokers/non-drinkers. Although the 
reasons remain unclear, this can be partly explained by the fact that these factors interact 
synergistically, increasing each other’s harmful effects. Findings from Blot et al. (2008) 
confirmed the results from several studies which have suggested the synergistic effects of 
smoking and drinking (Choi and Kahyo, 1991; Schlecht et al., 1999; Castellsagué et al., 
2004). Based on all of these research results, it has been calculated that 75 % of all oral 
cancer deaths could be prevented, and risk of dying of this cancer could be reduced by 
eliminating smoking and excessive drinking (Walker et. al, 2003; Ide et. al., 2008). 
Besides chemical factors, tobacco smoke, and alcohol, there are also some lifestyle and 
physical factors, as well as biological factors, which can have influence on the aetiology of 
these types of cancers. For example, there are studies which indicate a diet low in fruits 
and vegetables could be a risk factor and also exposure to ultraviolet radiation increases 
the risk of lip cancer (La Vecchia et al., 1997; Freedman et al., 2008). Furthermore, oral 
human papillomavirus (HPV) infection is also associated with oral cavity risks (Smith et 
al., 2004; Hansson et al., 2005; Pintos et al., 2008).  
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Survival rates 
 
Compared to other cancers, oral carcinoma has a poor prognosis (Franco et al., 1993; 
Sciubba, 2001; Shiboski et al., 2007). The quality of life in the late stages of the disease is 
poor. Factors such as delay in treatment, gender, age, ethnic group, tumour size, and 
therapy may influence oral carcinoma survival rates. Despite advances in surgery, 
radiation, and chemotherapy, the five-year survival rate for oral cancer has not improved 
over the past several decades (Silverman, 2001). Diagnosing oral cancer at an early stage 
significantly increases 5-year survival rates. Survival rates are presented in Table 2. 
 
Table 2. Relative 1-year, 5-year, and 10-year survival rates for male patients with oral 
cancer (Cawson and Odell, 2002). 
 
Disease stage Survival rate (males, %) 
 First years Five years 10 years 
Early stage 90 65 55 
Late-stage 45 16 12 
2.3 Acetaldehyde as a carcinogen and addictive agent 
Acetaldehyde (ethanal; CH3CHO) is a generally recognised as safe (GRAS) compound for 
use as a flavouring agent and adjuvant. It is still important chemical of food flavourings 
and is also added to milk products, fruit juices, desserts, and soft drinks. Considering that 
acetaldehyde is now classified as a carcinogen in humans (Group I) there is agreement that 
the GRAS classification of acetaldehyde should be reconsidered.  
Acetaldehyde, volatile aldehyde present in tobacco smoke, is known as a carcinogen in 
animals (Swenberg et al., 1980; Woutersen et al., 1986). When administered by inhalation 
in rats, acetaldehyde increased the incidence of carcinomas in the nasal mucosa. 
Administration of acetaldehyde in drinking water to rats caused hyperplastic and 
hyperproliferating changes in the tongue and the forestomach (Homann et al., 1997). 
Some results indicate that acetaldehyde may also increase the addictive potential of 
nicotine, and thus has possible role in smoking addiction (Adriani et al., 2003; Belluzzi et 
al., 2005). 
Theruvathu et al. (2005) showed that mutagenic and carcinogenic changes caused by 
acetaldehyde can occur at acetaldehyde concentration from 100 μM and above. A 
concentration of 100 μM can be found in saliva after moderate ethanol consumption 
(Homann et al., 1997). Some in vivo animal studies have also shown that administration of 
drinking water containing acetaldehyde to rats can cause hyperplastic changes in the 
tongue and in the stomach. In addition, there is increasing evidence that acetaldehyde, the 
first metabolite of non-carcinogenic ethanol, may be one important factor to explain the 
cocarcinogenic effect of alcohol (Boyle et al., 2003; Seitz et al., 2004). Furthermore, 
normally, after alcohol ingestion acetaldehyde is metabolised rapidly into harmless acetate 
by the aldehyde dehydrogenase (ALDH) enzyme. Väkeväinen et al. (2000) have shown 
that Asians with a mutant enzyme (ALDH2) have 2–3 times higher salivary acetaldehyde 
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levels after a moderate dose of ethanol than those Asians with normal ALDH enzyme. 
This genetic defect occurs in 30-50 per cent of Asian people. In Asian heavy drinkers, 
with this genetic inability to remove acetaldehyde, the risk of digestive tract cancers is 
markedly increased (Yokoyama et al., 1998). 
High amounts of acetaldehyde are also found in tobacco smoke. Hoffmann et al. 
(2001) showed that the amounts of acetaldehyde found in tobacco smoke vary within the 
range of 400–1400 μg/cigarette.  
2.3.1 Acetaldehyde from tobacco smoke 
Acetaldehyde is formed during the burning process and may be one of the most toxic 
compounds in tobacco smoke (Smith and Hansch, 2000; Seeman et al., 2002). The 
concentration of acetaldehyde in tobacco smoke is more than 1000 times greater than that 
of PAHs and N-nitrosamines. There is also some evidence that the concentrations of 
PAHs are too low to explain the carcinogenicity of the tobacco smoke (Pfeifer et al. 2002). 
Because the acetaldehyde from the smoke is dissolved into saliva, during the period of 
smoking only one cigarette, salivary acetaldehyde levels increase over 260 μM from the 
basal level of 0 (Salaspuro and Salaspuro, 2004). Since those acetaldehyde concentrations 
are clearly above the mutagenic level of 50 μM, acetaldehyde may provide one clear 
explanation for the increase risks of oral cavity, pharyngeal, and laryngeal cancers among 
smokers. Furthermore, it may also provide strong evidence for the increased risk of 
esophageal and stomach cancer among smokers (Gonzáles et al., 2004). That can partly be 
explained by the fact that as a part of saliva, acetaldehyde is transported by swallowing to 
the mucous membranes of the esophagus and stomach, where it can affect as a local 
carcinogen.  
Acetaldehyde has been considered in some studies to be addictive, in addition to the 
main, and the most well-known addictive component, nicotine (Adriani et al., 2003; 
Belluzzi et al., 2005).As such, in self administration studies, rats have been shown to 
consume five times more acetaldehyde/nicotine mixture than nicotine nicotine or 
acetaldehyde alone (Charles et al., 1983; Belluzzi et al., 2005). This effect may be due to 
harman and salsolinol, condensation products of acetaldehyde, which inhibit monoamine 
oxidase (MAO). Some MAO-inhibitors are known to increase nicotine self-administration. 
Interestingly, results also showed that the youngest rodents, compared to adult rodents, 
reacted significantly more to acetaldehyde/nicotine mixture than to saline or either drug 
alone. Taken together, these results indicate that acetaldehyde may increase the addictive 
potential of nicotine and also partly confirmed hypothesis that human youth are more 
sensitive to tobacco addiction than adults.  
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2.4 L-cysteine as a potential agent for reducing acetaldehyde 
2.4.1 Physicochemical properties and use of L-cysteine  
Cysteine (2-amino-3-sulfanyl-propanoic acid) is a sulfur-containing amino acid. It is a 
non-essential amino acid, which means that humans can synthesise it in the body 
(Finkelstein, 1990). Although classified as a non-essential amino acid, in some rare cases, 
L-cysteine may be also essential, e.g. individuals who suffer from malabsorption 
syndromes. L-cysteine’s chemical properties are listed in Table 3. 
 
Table 3. Physicochemical properties of L-cysteine (The Merck Index, 1996). 
 
Properties of L-cysteine 
 
Chemical structure 
 
 
 
 
Systematic name 
Molecular formula 
 
 
2-amino-3-sulfanyl-propanoic acid 
C3H7NO2S 
Molar mass 121.16 g/mol 
Appearance 
Melting point 
Solubility in water 
pKa 
White crystals or powder 
240°C 
Freely soluble in water and ethanol, 280 g/l 
1.71, 8.33, 10.78 
 
L-cysteine can be found from different natural sources, such as red peppers, garlic, 
onions, broccoli, and oats, with an estimated average intake of about 1 g/day. According to 
the  EU Commission, L-cysteine is considered to be a food additive with an acceptable 
daily intake (ADI) that is “not specified” (European Commission, 2012). The industrial 
source of L-cysteine is human hair, as well chicken feathers, and pig bristles. At this 
moment, 80 % of all industrial L-cysteine is prepared in China, where it is extracted 
particularly from human hair and chicken feathers. As L-cysteine is used not only in the 
pharmaceutical industry but also in the food industry, it should be taken into account that 
some cultures and religious do not allow the consumption of any part of the human or 
animal body. According to the EU directive 2000/63/EC, for L-cysteine (E-code: E 920), 
human hair may not be used as a source for this substance in EU countries (European 
Comission, 2000). Generally, that might be a serious issue and the facts about L-cysteine 
sources should be seriously considered in formulating L-cysteine containing products. 
As mentioned, L-cysteine is normally consumed as a food component and is 
considered as a safe component (Raguso et al., 2000). However, some studies have shown 
that administration of L-cysteine might act as a neuronal toxin in sites that lack the blood-
brain barrier (Meister, 1989; Janaky et al., 2000). The toxic L-cysteine dose in a 70 kg 
human is 80 g (Meister, 1989). 
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2.4.2 L-cysteine as acetaldehyde binding agent 
In the early 1970s, Sprince et al. (1974) presented a study in which protection against 
toxic acetaldehyde might be obtained with the thiol compound, L-cysteine. In the reaction, 
L-cysteine is able to protect from acetaldehyde toxicity by binding acetaldehyde and 
forming MTCA (Fig. 1). MTCA is suspected to be a non-toxic compound. 
 
 
 
 
 
 
 
 
 
Figure 1. Chemical reaction between acetaldehyde and L-cysteine forming MTCA 
(Sprince et al., 1974). 
2.4.3 Routes of administration and dosage form 
In order to get the best possible influence on acetaldehyde, L-cysteine should be 
administered locally (Salaspuro et al., 2006).  As a benefit of local administration, 
acetaldehyde is directly and immediately bound and the total amount of L-cysteine utilised 
should be as low as possible. Salaspuro et al. (2002) have shown that with a buccal tablet 
containing   100 mg of L-cysteine, it is possible to bind and thus to reduce acetaldehyde 
concentration formed during ethanol oxidation in the saliva (from 162.3 ± 34.2 μM x h to 
54.3 ± 11 μM x h). The same research group also showed that a locally administered 5 mg 
L-cysteine containing tablet can effectively eliminate acetaldehyde from the oral cavity 
during 5 minutes of smoking (Salaspuro et al., 2006). 
Taking into account that L-cysteine products are intended to be used by tobacco 
smokers, a dosage form may be a way to achieve good user compliance. To achieve as 
good user compliance as possible, design of a proper formulation is an increasingly 
important consideration. For example, compared to lozenges, chewing gum may allow 
better control of the release rate - since lozenges may be broken by biting, which again can 
result in rapid L-cysteine release from the lozenge.  
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2.5 Intraoral drug delivery  
2.5.1 Oral cavity as a route of administration 
The mean goal of local drug delivery (local effect) to the mouth is to treat conditions of 
the oral cavity, principally aphthous ulcers, fungal diseases, and dental care. In addition to 
local effect there is also a possibility of oral transmucosal delivery (systemic effect). In the 
case of systemic drug delivery, the aim is to achieve drug absorption through the mucosal 
barrier to reach the systemic circulation. The oral transmucosal route can be divided into 
two groups: sublingual (under the tongue) and buccal drug delivery systems. Sublingual 
drug delivery is used for the delivery of the drugs characterised by a high permeability 
across the mucosa. It is used in the treatment of acute disorders. Buccal drug delivery 
system is used in chronic disorders when prolonged release of drug and absorption is 
required. It is also an excellent route for the treatment of local mouth diseases. 
Intraoral drug delivery system is associated with many advantages, such as rich blood 
supply, elimination of hepatic first-pass metabolism, low dose related side effects, ease to 
use, low metabolic activity for oral delivery of enzymatically labile drugs, and good 
patient compliance (Scholtz et al., 2003; Sudhakar et al., 2006).  
Various types of formulations are used in intraoral drug delivery. Such dosage forms 
are liquids (e.g. sprays, syrups), semisolids (e.g. ointment pastes), and solid dosage forms 
(e.g. sublingual tablet, lozenges, chewing gums, patches) (Bukka et al., 2010). Since the 
experimental part of this thesis is more focused on chewing gum as a dosage form, it will 
be more discussed in section 2.6.   
The main challenge of oral mucosal drug delivery comes from the relatively small 
absorption area (~ 100 cm2) and from the barrier properties of mucosa and saliva. For 
example, swallowing and speaking, can reduce drug exposure to impair absorption. 
To fulfil therapeutic requirements, formulations designed for intraoral drug 
administration, should consider possible physiological changes in the oral cavity. The 
daily secretion of saliva normally ranges between 800 and 1500 ml but physiological and 
pathological changes can have an effect on saliva production, e.g. smell and taste 
stimulation, chewing, drugs, age, oral hygiene, and physical exercise (Chicharro et al., 
1998; Walsh et al., 2004). Even if saliva contains several organic and inorganic 
components, in general, those levels are very low and the main compound of saliva is 
water (99.5 %). Normally saliva is colourless with a pH between 6.7 and 7.4, but it can 
temporarily drop below 2 when sweets, carbonated fruit drinks, and other dietary acids are 
consumed (Hall et al., 1999; Diaz-Arnold and Marek, 2002; West et al., 2003; Jensdoir et 
al., 2005). In addition, the temperature, which is normally around 37 °C, can vary between 
+5 and +55 °C for short times, when eating or drinking cold or hot meals or drinks (Scholz 
et al., 2008). Some drugs, such as beta blocking agents, nitrates, and diuretics, as well as 
tobacco smoking can also reduce salivary pH (Birkhed and Heintze, 1989).  
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2.6 Chewing gum as a drug delivery system 
2.6.1 Use of chewing gum in drug treatment  
The arrival of nicotine chewing gum on the market in the 1980s opened a new field and 
interest in drug research – the use of medicated chewing gum. Chewing gums are an 
alternative drug delivery system when considering intraoral or per oral administration of 
drug substances. There are several established medical chewing gums on the market, and 
the best well-known are the NRT nicotine gums. Examples of medical chewing gums 
available worldwide, with their indication, are summarised in Table 4. The most 
significant advantage is the fact that active components of medicated chewing gums can 
be absorbed through the buccal mucosa and also through the gastrointestinal tract if saliva 
is swallowed (Christrup et al., 1990a, b). As a result, a systemic effect can be obtained. 
Chewing gum is also an effective drug-dosage form for local treatment of diseases of the 
oral cavity and throat (Rassing, 1996). Other advantages and disadvantages are listed in 
Table 5. 
 
Table 4. Some medical chewing gums available on the market worldwide (Meteti et al., 
2012). 
 
Active substance Indication Trade name 
Acetylsalicylic acid Analgesic Aspergum® 
Caffeine Attentiveness Stay Alert® 
Dimenhydrinate Travel sickness Trawell® 
Fluoride Cariostatic Flourette® 
Nicotine Smoking cessation Nicorette®, Nicotinelle® 
Xylitol Preventation of dental 
caries 
V6® 
 
Table 5. Summary of advantages and disadvantages of chewing gum as a drug delivery 
system (Rassing et al., 2003). 
 
 
 
 
Advantage Disadvantages 
Fast release of active substance Prolonged chewing on a gum may 
result in pain in facial muscles and 
earache in children 
Advantageous for patients 
having difficulty in swallowing 
Widely used excipients (e.g. sorbitol 
and xylitol) can cause diarrhea 
 
Less risk of overdose  Can adhere to teeth denture 
Acceptable by most age groups   
Avoids first pass metabolism   
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2.6.2 Chewing gum preparation 
Medical chewing gum consists of a tasteless gum base mixed with an active drug 
substance, softeners, flavour agents, and sweeteners. Medical chewing gum composition is 
listed in Table 6. 
 
Table 6. Components used in medical chewing gum (Pedersen and Rassing, 1990; 
 Rowe, 2003; Maggi et al., 2005). 
 
Component Function 
Drug 
 
Active compound 
 
Elastomers: 
Synthetic: styrene-butadiene rubber 
Natural: smoked rubber 
To provide the elasticity 
Resins (polyvinyl acetate) 
 
To improve texture; reduces the tendency of the gum to 
stick to the teeth 
Waxes (paraffin) Softening agents 
Emulsifiers (PEG 6000, glycerol) To promote the uptake of saliva 
Sweeteners (sorbitol, xylitol) To improve the taste and also as a non-cariogenic agent 
Flavours (citrus, pepermint) To improve the taste 
 
The traditional gum process is the most frequent method for manufacturing chewing 
gums. The first step in the traditional production process is melting of a gum base in a 
mixer to which other excipients, together with active compound, are added to the melted 
phase (Maggi et al., 2005). The next steps are cooling and rolling into sheets and the final 
step is cutting the mass into small pieces. The high temperatures (40-50 °C) used during 
the melting process are considered a big disadvantage of this preparation method.  
Recently, researchers have focused more on direct compression methods, which may 
avoid the high costs associated with traditional chewing gum production (Morjaria et al., 
2004; Maggi et al., 2005). Using a direct compression manufacturing process, the gum 
base, together with other chewing gum ingredients, can be rapidly compacted into a gum 
tablet using standard tablet press equipment. The low temperature used during the direct 
compression process, compared to traditional processes, protects thermally unstable active 
substances.  
Drug release from chewing gum is strongly dependent upon individual variability such 
as chewing frequency and intensity (Gavaskar et al., 2011). The release rate of an active 
substance is determined not only by the formulation of the chewing gum, but also by the 
properties of the physicochemical properties of active substance (Jacobsen et al., 2004). 
Thus, lipophilic substances, which many drug substances are, first adhere into the 
lipophilic gum base and then released slowly and incompletely. One method to achieve 
faster lipophilic substance release is increasing the amount of softeners. Thus, softer gum 
might offer faster drug release (Patel et al., 2011). Pedersen and Rasing (1990) have 
shown that the use of emulsifiers, such as PEG 6000, increased the release rate of 
miconazole. In contrast, hydrophilic active substances will show immediate release within 
a few minutes. Fast released drugs may be swallowed with saliva and thus, cause 
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unwanted side-effects in the gastrointestinal tract. Therefore, it might be necessary to slow 
down the release rate by increasing the amount of lipophilic gum base.  
2.7 Drug development process 
In 1878, Rudolf Buchhein wrote in his 1st Manual of Pharmacology “Long before a drug 
is used to cure an illness it must be our effort to receive the greatest possible amount of 
knowledge regarding the illness to be treated as well as the drug to be used. Equipped 
with this knowledge the observation of the effect on the patient must then lead us to the 
correct use of the drug”. Until now, that has remained unchanged (Kuhlmann, 1997). 
The development of a new therapeutic drug is a very long process and the costs are 
extremely high not to mention a high risk that it will not succeed. From highly potent 
candidates, only 8 % reach the market and it can take approximately 10–15 years and over 
800 million dollars to bring a drug from an idea to the market (DiMasi et al., 2003; FDA, 
2004; Vernon et al., 2010). Traditional drug development, from the idea to the product, 
may be divided into several steps: compound discovery, preclinical studies, clinical 
development, approval, and market (Kuhlmann, 1997). To make sure that a drug will be 
safe to humans, during preclinical development the drug has to be first tested under 
laboratory circumstances, in silico, in cells in vitro, and in animals in vivo. Therefore, 
results from the studies are utilised by preformulation experts to determine how to best 
formulate the drug to the next step, for clinical testing. Clinical trials in healthy volunteers 
and ill patients are essential for the development of a successful drug therapy (Kuhlmann, 
1997). This is due to the evident differences between animals and humans, and for 
example many diseases in humans do not occur in animals. Until now, a suitable animal 
model, not to mention in silico or in vitro cell model, has not yet been found for human 
diseases. However, animal studies, as well as in silico or cell models, can significantly 
minimise the risk for human patients and improve the drug development process.  
Clinical trials are classified into four steps, called phases (phase I-IV). Usually, the 
drug will be approved for use by national regulatory authorities if the drug successfully 
passes through Phases I-III. In the past (data from 1991), poor biopharmaceutical 
properties of compounds of  (40 %) have been considered to be the primary reason that 
many potential drug candidates fail from the clinical studies (Kola and Landis, 2004). 
However, due to the success rate on drug biopharmaceutical properties during 2000, 
nowadays, the main reason of drug failure in Phase II and III is considered to be 
insufficient efficacy of the drug (51% and 66 % correspondingly) (Table 7) (Arrowsmith, 
2011a, b; Khanna, 2012).  
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Table 7. The reasons for drugs failure in Phase II and III during the years 2007-2010 
(Khanna, 2012). 
 
 Phase II (%) Phase III (%) 
Efficacy  51 66 
Financial  
and/or Commercial  
29 7 
Safety  19 21 
Biopharmacokinetics 1 - 
Not disclosed - 6 
 
Taking into account the costs, time, and need for new medicines, it is clear that there is 
an urgent need to speed up the drug development process (FDA, 2004; Hunter, 2011). As 
such the traditional drug development process requires changes and a new way of 
operating is characterized by multidisciplinary approaches. Translational research builds 
the bridges from the early beginning between different science fields, pharmaceutical 
industry, and regulatory authorities. The main idea of translational research is to bring 
effective research from the “laboratory bench to the hospital bedside” and thus to cut costs 
and reduce the time required to reach the market. Some typical tools used in translational 
drug development are pharmacogenomics (personalised medicine), biomarkers, imaging 
tools, and modelling.  
The importance of different drug development tools used the in experimental part of 
this thesis will be discussed further in the text.   
2.7 1 Cell cultures as a tool in drug development 
Use of cell cultures 
 
Since in vivo experiments in laboratory animals and in humans are expensive and time 
consuming, in vitro methods are needed as part of the drug development process. The use 
of cell lines in the early stages of drug discovery might reduce cost and time typical of in 
vivo animal and human studies (Allen et al., 2005). Over the last twenty years, the human 
intestinal cell lines, such as Caco-2, HT29, and T84 have been used as an effective in vitro 
tool for estimation and prediction of human drug absorption (Huet at al., 1987; Dias and 
Yatscoff, 1994; Artursson et al., 2001; Andersson et al., 2012). Animal cell lines have also 
been used as in vitro models in drug development for intestinal absorption. Such cell lines 
are MDCK (Madin Darby canine kidney), 2/4/A1 (rat), and CHO (Chinese hamster 
ovary). Furthermore, human cell lines, such as HepaRG, are used also as in vitro tools for 
understanding drug metabolism and toxicology in humans (Andersson et al., 2012). 
Recently, tumour-derived human cell lines have been used to evaluate the therapeutic 
efficacy of cancer medicine candidates (Sharma et al., 2012). 
From another point of view, cells cultures are also used as well as a model for drug-
drug, drug-excipient, and for drug-food interactions during the absorption process (Rege et 
al., 2001; Laitinen et.al. 2003; Laitinen et al., 2004). Cell cultures are also widely used as 
an excellent tool to investigate cellular damage caused by different concentrations of a 
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drug and thus, to get the first view of possible human toxicity without expensive in vivo 
studies (Fotakis and Timbrell, 2005; Weyermann et al., 2005). The 3-[4,5-dimethylthiazol-
2yl]-2,5-diphenyltetrazolium bromide (MTT), the lactate dehydrogenase (LDH), the 
protein, and the neutral red (NR) assays are the most commonly used tests for the 
detection of toxicity of a drug. To increase the reliability of the results, it is suggested to 
use more than one assay.  
 
Caco-2 cells 
 
Caco-2 monolayers have been widely accepted by pharmaceutical companies, and also by 
regulatory authorities, as a standard in vitro model system, together with in vitro 
dissolution studies, to identify drugs with potential absorption problems and possibly to 
predict permeability and absorption of compounds in vivo (Artursson and Borchardt, 
1997; FDA, 2000; Artursson et al., 2001; Allen et al., 2005). Originally isolated from a 
colorectal carcinoma in the 1970s, Caco-2 cell monolayers express morphological and 
functional characteristics of mature small-intestinal enterocytes (Fogh et al., 1977; Pinto et 
al., 1983). However, because the tightness of the monolayer resembles more colonic than 
small intestinal tissue, it is not possible to mimic the exact situation in the small-intestine.  
It is well known that the transport of drugs across the intestinal epithelium may occur 
by one or more of four different routes: the passive transcellular and paracellular routes, 
the carrier mediated route, and by transcytosis. Comparison of drug transport in Caco-2 
monolayers with intestinal drug transport in vivo indicates that these monolayers can be 
used for drug absorption prediction by all four routes (Artursson et. al., 1993; Artursson et 
al., 2001). However, the best correlation to the in vivo situation is obtained for drugs that 
are transported by the passive transcellular route, which is known as the most common 
drug penetration route (Mandagere et al., 2002). Variations in culture conditions between 
different laboratories, and also different Caco-2 cell lines, still pose problems, resulting in 
different permeability results. Therefore, in permeability studies it is necessary to use one 
or several compounds, with well-known permeability properties as references.  
2.7.2 Dosage form in preformulation studies 
Considerations behind dosage form development 
 
As mentioned, the research and development of a new drug is an expensive and lengthy 
process. Therefore, to increase the productivity of drug development and the efficiency of 
new product it is extremely important to have studies a proper dosage form in early 
clinical, which, depending on results, can be further developed during the whole clinical 
process. For pharmaceutical companies, it is obvious that a new product should be well 
defined before any serious product development. The rush to get a final product from the 
laboratory to the market might be fateful to pharmacologically effective drug. Thus, to 
have as ideal a formulation as possible, there are several critical questions for formulation 
experts. These include the manufacturing process, compatibility studies between active 
drug and excipients and benefits for patients such as formulation functionality, efficacy, 
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convenience, and lifestyle. Thus, it is necessary to seriously observe product design from 
the early beginning of the dosage form development.  
It is well known that the physicochemical properties of raw material might a strong 
high influence on the kind of chosen manufacturing process. One good example of that is, 
as already mentioned, selection of chewing gum manufacturing process for temperature 
sensitive compounds. Successful formulation must be such that all components are 
physically and chemically compatible, including the active compound(s), excipients, and 
also the packaging materials (Verma and Garg, 2005; Mora et al., 2006). Thus, choice of 
proper excipients and packaging material for the final formulation is essential in 
formulation studies. The final formulation must also be well protected from microbial 
contamination as well from high temperature, light, and moisture. Furthermore, since most 
drugs have an unpleasant taste, during the whole development process, good acceptability 
by patients must be kept in mind (Rassing et al., 2003). It is especially important in 
develop of intraoral drug delivery systems. 
Since the experimental part of this thesis is also focused on the compatibility of active 
ingredient with excipients, it will be discussed further in following sections. 
 
Compatibility studies between drug and excipient(s) 
 
When the active compound is in contact with one or more excipients, and if potential 
physical and chemical interactions take place between drug and excipient(s), drug stability 
and bioavailability of the drug can be affected thereby affecting their efficacy and/or 
safety (Mura et al., 1998; Rahkola et al., 2000; Verma and Garg, 2005; Mora et al., 2006). 
Studies of drug-excipient(s) compatibilities are an important process in the 
development of a stable and proper formulation (Verma and Garg, 2005). Compatibility 
studies at an early stage helps in the selection of excipients to increase the probability of 
developing a stable dosage form; this actively improves the characteristics of 
formulations. It is essential to avoid incompatibilities, since it has been shown that 
interactions can result in therapeutic response of final product (Rahkola et al., 2000). 
Despite the fact that excipients can alter the stability and bioavailability of the final 
product, the general principles of selecting proper excipients are not well-defined.  
 
Methods used in compatibility studies 
 
There are many techniques which can be used to indicate interactions between a drug and 
excipient(s). Due to that, it is extremely important to choose methods for the evaluation of 
the solid state stability that give fast and correct information about existing incompatibility 
problems. 
Thermal analytical method, differential scanning calorimetry (DSC), which is one of 
the well-developed techniques, has been used to evaluate compatibility between drug and 
excipient(s) for over 30 years. The most important advantages of DSC are small sample 
amounts and rapid measurements. However, interactions observed at high temperature, 
close to melting point, may not be relevant under the real storage conditions (Rahkola et 
al., 2000). As a result, understanding of the results is often difficult and the possibility of 
making incorrect conclusions does exist (Tomassetti et al., 2005).  Accordingly, it has 
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been recommended that one method should be used in combination with another method. 
Fourier transform infrared (FT-IR) spectra can also offer fast information about 
interactions of a drug with different excipients. Additionally, standard high pressure liquid 
chromatography (HPLC), spectrophotometric analysis, as well as dissolution studies have 
been widely used in compatibility studies (Phipps and Mackin, 2000). Lately, isothermal 
microcalorimetry (IMC) is shown as a very useful technique. Compared to HPLC it is 
much faster and more sensitive.  
In 50:50 mixture compatibility studies with different methods, it is important to notice 
the real excipient concentration in the product. For example, magnesium stearate is 
incompatible with several active substances in 50:50 blends (Kerc et al., 1992; Mora et al., 
2006). However, those interactions are not too relevant as magnesium stearate was 
generally present in low amounts, typically within 0.5–2 % (w/w) range. 
 A schematic example of preformulation screening of drug-excipient interactions in a 
50:50 mixture of drug with the excipient is shown in Fig. 2. In all cases, the basic method 
is the same – mix together active compound with one or more excipient(s) and monitor 
any interactions (Schmitt et al., 2001). 
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Figure 2. Schematic example of preformulation screening of drug-excipient interactions 
in a 50:50 mixture of drug with the excipients (modified from Wells and 
Aulton, 1998). 
2.7.3 Computational modelling as a tool in drug development 
During the last decade both academics and pharmaceutical companies have paid more and 
more attention to modelling and simulation as a tool to reduce development cycle time and 
costs. Computer modelling might be used in drug discovery and development from the 
early beginning to evaluate potential compounds for clinical trials (Leahy, 2003). The 
challenge is to have as optimal formulation as possible at the beginning of clinical trials. 
In addition, the FDA (Food and Drug Administration) has recognised modelling and 
simulation as a valuable tool in drug development (Gobburu and Marroum, 2001). 
Computer modelling is an essential part of almost all scientific fields, and is widely used 
not only in pharmaceutical research, but also in biology, mathematics, physical, and social 
sciences.  
 
Model creating 
 
The first simulation model to predict pharmacokinetics was introduced by Bischoff and 
Dedrick in 1970, and as mentioned, nowadays predicting oral drug absorption in humans 
is a major goal. To create as useful a model as possible, it is important to answer the 
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critical questions: what do we want to know, what data should be obtained (Grass, 1997). 
Another important task of simulation models is to be able to take variability in 
physiological factors into account, such as bodyweight, gender, age, race background, 
food intake, or smoking habits. When necessary and preliminary data is collected, it is 
possible to start establishing a model (Burman et al., 2005).  Usually at the beginning, data 
is sourced from preclinical data, expert opinions, or combined data from published 
research papers. Furthermore, developed models can be updated and refined, depending on 
the results and new data.  
 
Use of simulation models  
 
Since animal drug experiments are not only an expensive tool, but also painful for 
animals, in silico methods, such as computational modelling, are needed to reduce animal 
studies in the early drug discovery, which is an extremely important issue. Drug discovery 
can benefit from modelling using fast and simple computational methods in early drug 
discovery stages to predict the absorption, distribution, metabolism, excretion and toxicity 
(ADME/T) properties of molecules (Khan, 2010). The model can be used to select proper 
drug candidates into early preformulation studies and for obtain answers on drug efficacy 
and safety in different patient populations. Thus, developed models can aid the design of 
clinical trials, in finding the population that benefits from the drug and furthermore, the 
running of successful clinical trials. As a result, modelling might facilitate the selection of 
the right drug candidate and thus reduce the risk of failure in clinical trials. 
Physiologically based pharmacokinetic (PBPK) simulation models are widely used in 
modelling the pharmacokinetics of drugs. Edginton and Willmann (2008) have developed 
a PKPB model, which can be used to predict drug pharmacokinetics in patients with liver 
cirrhosis. The model compared physiological differences (blood flow and reduced hepatic 
function) between healthy individuals and patients with liver cirrhosis. PBPK models are 
also widely used in paediatric medicine to minimise difficulties in clinical paediatric 
studies without compromising the well-being of paediatric patients in clinical studies 
(Bellanti and Pasqua, 2011; Khalil and Läer, 2011). 
Quantitative structure-property relationship (QSPR) models have also been developed 
to predict the ADME/T properties of drug candidates (Zhao et al., 2002; Linnankoski et 
al., 2006). Linnankoski et al. (2008) showed that intestinal absorption prediction of 178 
drugs is possible using computational modelling. As a result, models have shown that 
prediction of passive intestinal absorption is equal to in vivo prediction using Caco-2 and 
the 2/4/A1 cell lines. The same research has also shown that using simulation models, it 
was possible to predict the absorption of 65 selected drugs almost equally to absorption 
studies with rats.  
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3 Aims of the study 
Elimination of acetaldehyde, not only carcinogen, but also agent which possibly increases 
the addictive potential of tobacco, might help in the fight against smoking and make 
smoking cessation programs more efficient. The ultimate aim of this study was to, through 
preformulation studies investigate, L-cysteine’s ability to eliminate carcinogenic 
acetaldehyde from saliva with developed chewing gums.  
 
The specific aims were: 
 
1. To develop user-friendly L-cysteine containing chewing gum to reduce tobacco 
smoking carcinogenic acetaldehyde using two alternative chewing gum 
manufacturing methods, namely the traditional method and much simpler and 
cost effective direct compression method. The main three variables were: (1) 
chemical form of cysteine (L-cysteine or L-cysteine hydrochloride), (2) the 
amount of active ingredient in the gum and (3) manufacturing procedure 
(traditional or direct compression method) (I). 
 
2. Since changes in temperature and humidity during chewing gum manufacture 
and product storage might affect product stability, it was important to 
determine whether temperature or humidity could affect L-cysteine stability. 
The aim was also to determine possible interactions between L-cysteine and 
some excipients which are commonly used in direct compression (II). 
 
3. To analyse the roles of different physiological factors and the effect of 
formulation parameters on acetaldehyde in tobacco smoke using a 
computational model. Physiological factors studied were changes in salivary 
excretion rate. Formulation variables were changes in L-cysteine amount (III).   
 
4. To determine whether L-cysteine or MTCA, the compound formed in reaction 
with acetaldehyde and L-cysteine, could be absorbed through the Caco-2 cell 
lines.  The study was done to get more information on the ability of the 
compounds to absorb from the gastrointestinal tract. The aim was also to 
determine safety of   L-cysteine and MTCA to the cells. Since stable MTCA in 
different parts of the gastrointestinal tract is wanted, the aim was also to 
determine the stability of MTCA (IV). 
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4 Experimental 
4.1 Chemicals (I-IV) 
The chemicals used in the studies are listed in Table 8.  
 
Table 8.  Summary of the chemicals used in the publications I-IV. 
 
Chemical Producer/Supplier Publication 
1% NEAA (non essential amino 
acids)  
Euroclone, Pero, Italy IV 
14[C]-mannitol Amersham-Pharmacia Biotech 
UK Ltd, Amersham, England 
IV 
Acetaldehyde Sigma, St. Louis, MO, USA IV 
Ethylenediaminetetraacetic 
acid disodium salt dehydrate 
(Na2EDTA) 
 III, IV 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) 
 IV 
MES (2-(N-
morpholino)ethanesulfonic acid 
 IV 
MTT (3-[4,5]-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium) 
 IV 
Tetrabutylammonium 
hydrogensulfate 97% (TBAHS) 
 IV 
10% trichloroacetic acid  III, IV 
Tri-n-buthylphosphine  III, IV 
Acetonitrile Rathburn, Walkenburg, Scotland IV 
Ammonium 7-fluorobenzo-2-
oxa-1,3-diazole-4-sulfonate 
(SBD-F) 
Fluka Chemicals, Buchs, 
Switzerland 
III, IV 
Boric acid  III, IV 
Dinatrium hydrogenphosphate 
(Na2HPO4)  
 IV 
L-cysteine  I-IV 
Black currant flavoring Quest International, Naarden, 
the Netherlands 
III 
Calcium dichloride (CaCl2) Sigma- Aldrich, Seelze, 
Germany 
III 
37% hydrochloride acid (HCl)  III 
Potassium dihydrogen 
phosphate (KH2PO4) 
 III 
Sodium bicarbonate (NaHCO3)  III 
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Table 8. (Continued). 
 
Sodium hydrochloride (NaCl)  III 
Sodium hydroxide (NaOH)  III, IV 
DMEM (Dulbecco’s Modified 
Eagle Medium) 
Gibco Invitrogen Corporation, 
Carlsbad, CA, USA 
IV 
1 % L-glutamine  IV 
HIFBS (Heat inactivated fetal 
bovine serum) 
 IV 
HBSS 10x concentrate (Hanks’ 
balanced salts solution) 
 IV 
Penicillin (100 IU/ml)  IV 
Streptomycin (100 μg/ml)  IV 
0.25 % trypsin,  IV 
Every T Toco Gum Base Company S.p.A., Italy I, II 
Smily 2 Toco  I, II 
Ferric sulfate J. T. Baker, 
Netherlands 
I,II,III 
Ferrozine  Sigma-Aldrich ChemieGmbH, 
USA 
I,II,III 
L-cysteine hydrochloride Quimicos, Gonmisol S.A., 
Barcelona, Spain 
I,II 
Lemon flavour Quest International, Netherlands I,II 
Magnesium stearate 
Mannitol 
Merck, Darmstadt, Germany I, II, III 
Orthophosphoric acid  III, IV 
Potassium chloride (KCl) 
 
 III 
Methanol  
 
Rathburn, Walkenburg, Scotland III, IV 
N,N-Dimethylformamide  Sigma-
Aldrich, Steinheim, Germany 
III, IV 
Pharmagum S SPI Pharma, New Castle, USA I,II 
Sodium perchlorate 
 
Sigma-Aldrich ChemieGmbH, 
USA 
I, II,III 
Sorbitol 
Xylitol 
Roquette, Lestrem Cedex 
France 
II                                         
I, II 
4.2 Methods 
4.2.1 Study formulations  
 
Direct compression method (I, II, III) 
 
Two different chewing gum formulations were prepared. One formulation (A) contained 
7.7 mg of L-cysteine and the other (B) 10.0 mg of L-cysteine hydrochloride, 
corresponding to 7.7 mg of L-cysteine.  Pharmagum S was used as a gum base and lemon 
flavour was used as a flavouring agent to disguise the unappealing taste of L-cysteine. All 
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components of these two formulations, except for magnesium stearate, were mixed for    
20 min in a Turbula shaker mixer (T2C Willy A. Bachofen A6 Maschinenfabrik, 
Switzerland). Magnesium stearate was added to the formulations at the end of the mixing 
and then it was mixed for two more minutes. The total weight of chewing gum was 1080 
mg. Chewing gums were compressed with an instrumented eccentric tablet machine 
(Korsch EK-0, Erweka Apparatebau, Germany) using flat faced punches with a diameter 
of 13 mm. The applied compression force was 7–8 kN. 
Tablets used in publication III containing 5 mg of L-cysteine were prepared as above. 
Mannitol (725 mg) was used as a filler and black currant (20 mg) as a flavouring agent. 
 
Traditional method (I) 
 
Three formulations were prepared using the traditional gum process by Fennobon Oy, 
Karkkila, Finland. The first formulation contained 10 mg of L-cysteine hydrochloride 
(equivalent to 7.7 mg L-cysteine) and the second one contained 6.5 mg L-cysteine 
hydrochloride (equivalent to 5.0 mg of L-cysteine). The third chewing gum formulation 
was a placebo containing no L-cysteine. Each chewing gum contained gum base and 
sweeteners such as xylitol and sorbitol as the major ingredient components. The other 
excipients present in small amounts in formulations were: flavours, thickener, humectant, 
emulsifier, artificial sweeteners, food colour, and glazing agent. The total weight of 
chewing gum was 1080 mg. In preparation, the gum base of chewing gums was heated at a 
temperature between 40 and 50 °C for melting. After that, L-cysteine hydrochloride was 
added along with the other components. After mixing, the homogenous chewing gum 
mixture was cooled, cut into squares, and hardened at room temperature. The pieces were 
then coated with xylitol in a coating drum, and finally polished. All formulations were 
shaped to be similar in weight, colour, and size. 
4.2.2 Solid-state stability (II, IV) 
Active compounds, in addition to a 1:1 (w/w) physical mixture of active compound and 
excipients (n = 6), were prepared by gently mixing the components with a spatula, and 
stored in stability test chambers (KBF 115, Binder GmbH, Germany) as follows: in tightly 
closed and open amber glass vials at 25 °C/60 % RH (relative humidity) and in tightly 
closed and open amber glass vials at 45 °C/75 % RH. The compatibility of L-cysteine with 
xylitol, sorbitol and two gum bases, Every T Toco and Smily 2 Toco, were also studied. 
The remaining amounts of L-cysteine were analysed spectrophotometrically immediately 
after mixing and then at regular intervals (1, 2 and 3 weeks and 1, 2 and 3 months) by the 
method described in Eid (1998).  
Solid-state stability studies have also been done for pure MTCA at the same 
temperature and humidity conditions as mention above. The remaining MTCA was 
analysed by HPLC method immediately and after 1, 2, 3, 4, 8, and 12 weeks. 
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FT-IR (II) 
 
The L-cysteine and 1:1 (w/w) physical mixture of active compound and excipients was 
prepared by gently mixing the components with a spatula, and was stored in stability test 
chambers at 25 °C/60 % RH for over 10 days. Pellets of samples were scanned over a 
wavenumber range of 4000 cm−1 to 550 cm−1. Differential spectra were evaluated and 
interactions were determined by comparing differential spectra with that of pure L-
cysteine as either a free base or a salt. 
 
IMC (II) 
 
A 2277 Thermal Activity Monitor (TAM) (ThermoMetric AB, Sweden) microcalorimeter 
was used. The measurements were carried out at 25 °C and 45 °C. At both temperatures, 
measurements were carried out without an extra moisture source and with a controlled 
relative humidity atmosphere. The relative humidity inside the sample ampoule was 
controlled with a saturated salt solution in a miniaturised ampoule. At 25 °C, a saturated 
salt solution of NaBr was used to maintain about 60 % RH, and at 45 °C, NaCl was used 
to maintain about 75 % RH. Before measuring started under the regulated humidity 
atmospheres (25 °C/60 % RH and 45 °C/75 % RH), pure components were stored under 
measuring conditions for at least 10 days. In each case, the samples of pure L-cysteine (as 
a free base or salt) and excipients, in addition to the binary mixtures, were prepared and 
measured in duplicate. Samples were weighed into glass ampoules and sealed with teflon-
coated discs of rubber and aluminium caps. An empty sealed glass ampoule was used as a 
reference. The ampoules were inserted into the pre-equilibrium state of the calorimeter 
(referred as t=0 s) for 20 min, after which they were lowered into the final measurement 
position. The electrical calibration was performed each time after the temperature was 
changed. Data were collected using the dedicated Digitam (ThermoMetric AB, Sweden) 
software. 
4.2.3 Solution-state stability of MTCA (IV) 
The stability of the MTCA in the buffer solutions used in permeability studies, HBSS 
buffer containing 10 mM HEPES (pH 7.4) and HBSS containing MES (pH 5.5), was 
measured with an HPLC method as described below.  Samples were taken immediately 
and at 15, 30, 45, 60, 90 min, and at 2, 3, 4, 5, 6, and 24 h and analysed immediately.   
4.2.4 L-cysteine stability in chewing gum (II) 
Chewing gums were stored in stability test chambers (over a period of three months in the 
same conditions as mentioned in 4.2.2 paragraph (n = 6). The remaining amount of L-
cysteine was analysed spectrophotometrically as described in Eid (1998) immediately after 
chewing gum preparation and then at regular intervals (1, 2 and 3 weeks, and 1, 2 and 3 
months). 
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Drug compressed on a hydraulic press (II) 
 
A L-cysteine sample of 250 mg (n = 4)  was weighed and compressed on a hydraulic press 
(Carver model C laboratory press; Menomonee, WI) at 185 MPa to study the influence of 
compaction on the pure L-cysteine stability. Uncompressed powder was used as a control. 
The remaining amounts of L-cysteine were immediately analysed spectrophotometrically 
as mentioned above. 
4.2.5 Dissolution studies (I, IV) 
Dissolution tests of pure L-cysteine were carried out with 20 mg of L-cysteine powder, 
using the basket method described in USP 24 in 500 ml of distilled water and also in 
artificial saliva, pH 7.4 and 4.7, at 37 ± 0.5 °C. The artificial saliva was prepared as 
described by Duffó (2004): 4.201 g NaCl, 0.151 g KCl, 0.149 g CaCl2 and 0.104 g 
NaHCO3 were dissolved in pure water (500 ml), pH adjusted with HCl. The speed of 
rotation was 50 rpm. The drug concentrations were determined by spectrophotometry as 
described in Eid (1998).  Dissolution test was statistically analysed with Microsoft Excel 
2002 using two-way ANOVA. P < 0.05 was considered statistically significant. 
4.2.6 Cell culture studies (IV) 
Cell cultures (IV) 
 
Caco-2 (wild type) cells obtained from the American Type Culture Collection (Rockville, 
MD, USA), were maintained at +37 ºC in an atmosphere containing 5 % CO2 at 95 % RH. 
The cells were grown in a medium containing DMEM, 10% HIFBS, 1% NEAA, 1% L-
glutamine, penicillin (100 IU/ml), and streptomycin (100 μg/ml). The medium was 
changed three times per week. The cells were harvested weekly from plastic flasks        
(75 cm2) with 0.25 % trypsin. The cells were seeded at 6.8 x 104 cells/cm2 in 12-well 
Transwell® insert plates.  
 
MTT toxicity test (IV) 
 
Caco-2 cell viability was determined by MTT assay after test compound treatment (90 
min), to measure the mitochondrial activity of the cells. The tested concentrations of both 
compounds were: 75, 150, 300, 600, and 1200 μg/ml. The cells were exposed to L-
cysteine and MTCA for 3 h at 37 ºC. The intensity of the developed color was measured at 
a wavelength of 590 nm, using a Varioskan Flash spectral scanning multimode reader 
(Thermo Electron Corporation, Vantaa, Finland).  
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Permeability studies (IV) 
 
Transport of L-cysteine and MTCA across the Caco-2 monolayers was studied both in the 
apical to basolateral and basolateral to apical directions at pH 7.4 and 5.5. The cell 
monolayers were first washed twice with HBSS buffer containing 10 mM HEPES (pH 
7.4) or MES (pH 5.5) and then equilibrated for 30 min in the washing buffer solution. The 
apical solution was then changed to HBSS buffer containing the test compound              
(L-cysteine or MTCA for their respective permeability studies). The used concentrations 
for the test compounds were 150, 300, and 600 μg/ml. The samples were taken from the 
receiver compartment at 15, 30, 45, 60, 90, and 120 min and replaced immediately with 
the buffer. The concentrations of L-cysteine and MTCA were analysed, using the HPLC 
method as described below.  
4.2.7 Analytical methods  
 
Determination of acetaldehyde by gas chromatography (I) 
 
Acetaldehyde levels were measured by headspace gas chromatograph (Perkin Elmer, 
Norwalk, CT, USA) as described by Salaspuro et al. (2006) with slight modifications. A 
sample of saliva (500 μL) was immediately transferred into a headspace vial and stored at 
5–8 ºC for less than 1 h before assay. Gas chromatography conditions were as follows: 
column 60/80 Carbopack B/5% Carbowax 20 M, 2 m x 3 mm (Supelco, Inc., Bellefonte, 
PA, USA), oven temperature 37 ºC, transfer line and detector temperature 150 ºC. Each 
sample was made in duplicate. 
 
Determination of L-cysteine and MTCA by HPLC (III, IV) 
 
L-cysteine was determined by the methods described by Zappacosta et al. (1999) and 
Frick et al. (2003). For MTCA, the method was slightly modified from that described in 
Alary et al. (1989). 
The samples were analysed with a Waters HPLC apparatus (Waters Millennium, 
USA). The samples were done in triplicate. L-cysteine with a Waters 486 fluorescence 
detector, 717 autosampler, and the 510 pump, MTCA with a Waters 484 tunable 
absorbance detector at 210 nm. The mobile phase for L-cysteine was: 0.1 M KH2PO4 with 
5% methanol, adjusted to pH 2.7 with 85 % orthophosphoric acid. The mobile phase for 
MTCA was acetonitrile with Na2HPO4-TBAHS solution (5:95 v/v), adjusted to pH 6.5. A 
SunFireTM C-18 column was used (150 mm x 4.6 mm; Waters, Ireland) with flow rate of 
1.5 ml/min for L-cysteine and 1 ml/min for MTCA. The injection volume for L-cysteine 
was 10 μl and total analysis time 7 min (retention time ~ 4 min). For MTCA, the injection 
volume was 5 μl and total analysis time 10 min (retention time ~ 1 min). For L-cysteine 
the fluorescence intensities were measured with excitation at 385 nm and emission at    
515 nm. In both cases, the standard curves were linear over the concentration range used 
(50-600 μg/ml). 
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4.2.8 In vivo studies (I, III) 
Effect of L-cysteine chewing gums on salivary acetaldehyde (I) 
 
Six volunteers took part in the studies: five active smokers (> 10 cigarettes per day) and 
one habitual smoker (< 10 cigarettes per week) (4 men, 2 women; mean age                    
32 ± 12 years). The study was approved by the Coordinating Ethics Committee, Hospital 
District of Helsinki and Uusimaa (Finland). 
 
Effect of saliva pH on L-cysteine in saliva (III) 
 
Six volunteers took part in the studies (three males and three females, mean age               
31 ± 8 years). The volunteers sucked 4 mg of pure L-cysteine or a tablet containing 4 mg 
of L-cysteine for 5 min. Saliva was collected continuously for 2.5 min before the test, 
during the 5 min of the test and for 5 min after the test. Saliva for each 2.5 min interval 
was collected into separate collection tubes, yielding five samples altogether. All 
volunteers had normal, healthy saliva pH (mean pH 7.4 ± 0.3). To lower the saliva pH to a 
mean of 4.7 ± 0.4, the volunteers sucked a small amount of citric acid for 1 min before the 
test started. 
 
The chew-out study (I) 
 
The in vivo release of L-cysteine from chewing gums was studied by chew-out studies. 
Each volunteer chewed one piece of each chewing gum formulation at a rate of 12–15 and 
30–35 chews in 1 min. At the beginning of chewing, the gum crumbles into small 
fragments, which tongue movements bring together to form a gum. Gum that had been 
chewed for 1 min was frozen overnight at −40 ºC and then ground in a grinder to obtain a 
fine powder. The concentration of L-cysteine was determined as described in Eid (1998).  
 
Effect of L-cysteine chewing gums on salivary acetaldehyde (I) 
 
The effect of chewing gums containing L-cysteine as free base or as hydrochloride salt 
was tested in five active and one habitual smoker (4 males and 2 females; mean age        
32 ± 12 years). In each test, one cigarette was smoked in five minutes. During the first 
smoking period, volunteers chewed a placebo chewing gum. For the remaining four 
smoking periods, each volunteer chewed one piece of each kind of four chewing gum 
formulations at 12-15 chews/min for five minutes. After five minutes smoking was 
stopped and chewing gum spat out. Saliva samples were collected as mentioned above. All 
volunteers were instructed not to swallow any saliva. All subjects refrained from drinking, 
eating, or smoking half an hour before saliva collection.  The results of in vivo studies 
were analysed by two-way analysis of variance using Microsoft Excel. P < 0.05 was 
considered as statistically significant. 
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4.2.9 PAEM (Prediction of drug Amount and Effect in the Mouth) model (III) 
 
The computational model presented here was built using Stella® modeling software (Stella 
v9.0.2, isee systems, Inc.). The model was based on results described in publication III as 
well as previous results from our research group described in Salaspuro et al. 2006. In in 
vivo studies, salivary acetaldehyde increased rapidly during smoking to 228 ± 115 μM 
from the basal level (0) and declined rapidly after 5 minutes of smoking. The use of a L-
cysteine containing tablet during the 5 minutes of smoking binds and thus eliminate 
acetaldehyde. Acetaldehyde production in the saliva during smoking was modelled as a 
zero-order process of 5 min duration. Release of L-cysteine from the formulation to the 
saliva was modelled to mimic in vitro data. The reaction kinetics of acetaldehyde binding 
and swallowing of the saliva was also mechanistically modelled. A simulation model for 
the prediction of drug amount and effect on carcinogenic acetaldehyde in the mouth was 
named PAEM. 
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5 Results and discussion  
5.1 In vivo characteristics of L-cysteine 
5.1.1 Effect of saliva pH on L-cysteine (III) 
The in vivo results, where it was shown that saliva pH changes did not affect the 
remaining amount of L-cysteine, were in good accordance with the in vitro dissolution 
studies (III, Fig. 2, 3). As a result, it is possible to conclude that the stability of L-cysteine 
is not pH dependent and is stable in saliva. This is an important result, since it is it is well 
known that some diseases, consumption of acidic drinks and tobacco smoking can reduce 
saliva pH (Parvinen, 1984). Thus, the L-cysteine product developed is effective for not 
only users with normal, healthy saliva pH but also for those with lower saliva pH. 
5.1.2 The chew-out study (I) 
The results of the in vivo chew-out study indicated, that the active ingredient both as 
hydrochloride salt and also as base form, releases fairly quickly taking into account that 
smoking a cigarette takes about 5 minutes (I, Fig. 2). These findings are understandable, 
because the physicochemical properties of an active ingredient plays an important role in 
the release of drug from chewing gum formulations (Shrinivares et al., 2005). This might 
be explained on the basis that L-cysteine, as water soluble ingredient, released within few 
minutes, but lipid soluble drugs for example, are released first into the gum and then 
released slowly into the mouth.  
Another important finding from this study was that release of L-cysteine from 
traditionally prepared chewing gum was about one-third slower than that of the directly 
compressed chewing gum (P<0.001) (I, Fig 2). This result was expected since directly 
compressed gum first broke down into smaller fragments, which increase surface area and 
cause a rapid initial release of the active ingredient (“crumbing effect”). To achieve better 
user compliance, this characteristic should be avoided. This study also indicated that a 
lower chewing frequency ensures more prolonged release for the L-cysteine from the 
directly compressed formulation (I, Fig 2). In addition, chewing frequency did not have an 
effect on drug release from traditionally prepared formulation. Since in vivo chew-out 
studies include disadvantages, such as lack of chewing and variations in the flow and 
compositions of volunteer’s saliva (Runwal, 2008), to increase the reliability of the results 
it would also be essential to examine if there is a correlation in release rate between the in 
vivo chew-out results and the in vitro dissolution study.  
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In general, it might be concluded that formulation such as chewing gum might be a 
proper drug delivery system for fast onset due to the rapid release of L-cysteine in the oral 
cavity. Compared to traditional manufacturing processes, the directly compressed chewing 
gum method is much simpler and cheaper than that of the traditional chewing gum. 
5.1.3 Effect of L-cysteine on salivary acetaldehyde (I) 
From the results in Fig. 3 (I), it is evident that chewing a placebo gum in itself does not 
have an effect on saliva acetaldehyde levels during smoking. All tested L-cysteine 
containing chewing gum formulations reduced salivary acetaldehyde levels during five 
minutes of smoking to below the in vitro mutagenic level (50 μM). However, measurable 
acetaldehyde levels in saliva samples collected between 2.5 and 5 minutes were found 
with two formulations: directly compressed formulations containing 10 mg of L-cysteine 
hydrochloride, and traditional chewing gum containing 6.5 mg of L-cysteine 
hydrochloride. An explanation for that might again be found in the manufacturing process 
as well as the physicochemical properties of the active ingredient. It is also evident from 
the results that after five minutes of smoking, low saliva acetaldehyde levels were found in 
all study experiments. Since acetaldehyde levels are high only during smoking (for about 
5 min) and L-cysteine effect is needed during that time, it is important to conclude that it 
is a wanted effect. However, it should be noted that this kind of formulation is not ideal 
for longer smoking periods, e.g. during cigar smoking (Salaspuro et al., 2006). As it was 
mentioned in the literature part of this thesis, the toxic dose of L-cysteine in a 70 kg 
human is 80 g. That is much higher than the maximum dose suggested by these in vivo 
studies.  
The in vivo studies of Salaspuro et al. (2006) also showed that tobacco smoke 
carcinogenic acetaldehyde could be totally eliminated in the saliva during five minutes 
smoking by sucking a tablet containing 5 mg of L-cysteine. However, the disadvantages of 
sucking a tablet (lozenge), e.g., dry mouth, when lozenges can stick to the oral mucosa 
and/or tongue and might also, in some cases cause local irritation by sucking, that might 
impact user acceptability (Sreebny et al., 1992; Codd and Deasy, 1998). If so, and because  
L-cysteine containing product is purposed to use during every tobacco smoking,              
L-cysteine chewing gum might be more acceptable to users.  
As already mentioned, acetaldehyde is classified by IARC in Group 1, as a carcinogen 
to humans, but it is also an agent which possibly increases the addictive potential of 
tobacco. Thus, reducing carcinogenic acetaldehyde from tobacco smoke is needed. In 
addition, the fact that over one milliard people smoke, and that most smokers want to quit 
but most attempts fail (Croghan et al., 2003), make this importance of great worth. In 
conclusion, elimination of tobacco smoke carcinogenic acetaldehyde by L-cysteine 
containing chewing gum can open a new method, not only to lower the risk of 
development of upper gastrointestinal track cancers, but it may also play a significant role 
in fighting against tobacco addiction. It should also be remembered that acetaldehyde 
might be swallowed with saliva and carried further to the oesophagus and stomach, where 
it can induce cancer. Still, it should be kept in mind that acetaldehyde elimination does not 
make smoking completely harmless and tobacco smoke contains other carcinogens and 
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addictives. In the future, more clinical trials are needed to support the thesis findings of L-
cysteine reducing effect on carcinogenic acetaldehyde.  
5.2 In vitro characteristics of L-cysteine 
5.2.1 MTT cytotoxicity (IV) 
In vitro MTT-cytotoxicity of L-cysteine was examined prior to permeability studies. 
MTT-test demonstrated that L-cysteine, as was expected for an amino acid, was not toxic 
to the Caco-2 cells (IV, Fig. 5). The results showed in vitro that the formulation used to 
bind acetaldehyde might possibly also be safe in vivo.  
5.2.2 Caco-2 permeability studies (IV) 
Caco-2 cells were used to evaluate the permeability of L-cysteine at concentrations 150, 
300, and 600 μg/ml at pH 7.4 and 5.5 (IV). The permeability studies showed that the L-
cysteine concentrations in the receiver chamber were lower than the quantitation limit   
(50 μg/ml) of the HPLC method used. Thus it can be concluded that, L-cysteine was not 
absorbed at pH 7.4 as well as 5.5 and at all tested concentrations through the Caco-2 
monolayer. These in vitro results indicate that when administered locally to the mouth, 
stomach, or colon, where no LAT2 (which is known to be responsible for the absorption 
of L-cysteine in the small intestine; del Amo et al., 2008) is present, only a minimal 
amount of L-cysteine is absorbed.  
According to the permeability studies, it is possible to conclude that the L-cysteine 
dissolved from products for local use in the mouth will probably leave the site of 
administration only by binding to acetaldehyde, or if L-cysteine is being swallowed with 
saliva, it may also be considered as a dietary amino acid in the gastrointestinal tract. 
 
5.2.3 L-cysteine stability (II) 
Pure L-cysteine (II) 
 
Under tested circumstances it was found that pure L-cysteine, as free base or as a salt, was 
stable. Compared to the initial amount, there were no significant differences in the 
remaining L-cysteine amount after three months (II, Table 1). 
Since this thesis is partly focused on the chewing gum manufacturing process the 
compression effect on pure L-cysteine was also studied (II). Compared with the remaining 
amounts of L-cysteine before and after compaction on a hydraulic press, it is possible to 
make a conclusion that compaction affected the remaining amounts of L-cysteine     
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(Table 8). One explanation for this phenomenon might be found in that at elevated 
temperatures temperature-sensitive thiol, such as L-cysteine, is oxidised to cystine (Tan et 
al., 2003).  
Thus, to minimize unwanted active compound degradation in manufacturing planning 
processes should include not only the stability of the drug in powder mixtures with 
excipients, but also the effect of the manufacturing process (e.g. compression). For such 
temperature sensitive compounds unwanted degradation during the manufacturing process 
might be avoided by choosing a proper manufacture process, e.g. cooling process before 
compaction (Athanikar and Gubler, 1999). 
 
Table 8.  Remaining amount of L-cysteine (%) before and after compaction on a 
hydraulic press of 185 MPa (n=4). 
 
 
L-cysteine in 1:1 mixture with excipients (II) 
 
Some of the results from the compatibility of chewing gum excipients with L-cysteine at a 
1:1 (w/w) ratio are showed in Table 9. Xylitol and sorbitol were chosen because of their 
wide use in chewing gum products, and Pharmagum S and magnesium stearate are the 
mean excipients of the directly compressed chewing gum used in those studies. The 1:1 
(w/w) ratio was chosen to maximise the likelihood of observing any interaction (Mora et 
al., 2006).  
The incompatibility results, using either a solid-stage method, FT-IR or IMC, indicated 
that L-cysteine as a free base is more stable with different excipients than its salt form. In 
both cases, L-cysteine was incompatible with magnesium stearate. According to the 
literature magnesium stearate is incompatible with several active substances in 50:50 
blends (Kerc et al., 1992; Mora et al., 2006). Since magnesium stearate is generally 
present in low amounts (0.5–2 % (w/w)), those interactions are not too relevant. 
L-cysteine as a salt was incompatible with all used excipients and results with all used 
methods were in agreement (II, Table 1; Table 2). In addition, free base form with 
different excipients was sensitive to temperature and humidity, and as a result, the 
remaining amount of L-cysteine decreased (II, Table 1; Table 2). An explanation for that 
might be found in the hygroscopic characteristics of excipients (Airaksinen et al., 2005). If 
so, when they are exposed to humidity, the absorbed moisture works as a source of water 
solvent for L-cysteine. As a result, L-cysteine could have been dissolved and degraded.  
The compatibility studies were useful in determining the properties of developed 
chewing gum formulations and aided further development of the gum. Incompatibilities 
between drug and excipient(s) can affect the drug stability and bioavailability of the drug, 
and therefore, affect their efficacy and/or safety (Mura et al., 1998; Rahkola et al., 2000; 
 
 
Remaining amount (%) 
 L-cysteine 
free base 
L-cysteine         
hydrochloride 
Uncompressed powder 100±0.6 100±0.8 
Compressed powder 88.5±3.8 89.8±4.7 
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Verma and Garg, 2005; Mora et al., 2006). According to the results, the final product must 
be well protected from temperature and humidity during its shelf-life.  Since the purpose 
of the product is to be used during tobacco smoking, that might impact user’s 
acceptability. 
 
Table 9.  Interaction occurrence in binary mixture 1:1 (w/w) of L-cysteine two forms 
 with excipients determined with three different methods: solid-stage method, 
 FT-IR and IMC at 25 °C/60 % RH closed/opened vials. 
 
 
Mixture components 
 
3 months solid-stage at: 
25 °C/60 % RH 
closed/opened vials 
 
FT-IR 
 
IMC at: 
25 °C/60 % RH 
closed/opened vials 
 
L-cysteine:    
Xylitol No Yes No 
Sorbitol No Yes No 
Pharmagum S No No No 
Magnesium stearate No Yes No 
L-cysteine 
hydrochloride: 
   
Xylitol Yes Yes No 
Sorbitol Yes Yes Yes/Not measured 
Pharmagum S Yes Yes Yes/Not measured 
Magnesium stearate Yes Yes Yes/Not measured 
 
L-cysteine stability in chewing gum (II) 
 
In both chewing gum formulations, containing L-cysteine as a free base or as a salt, the 
remaining amount of L-cysteine at initial were found to be less than 90 % of that 
originally added .  As mentioned, this might be explained on the basis that temperature can 
increase during compression and therefore tableting can have an effect on temperature-
sensitive compounds (Picker-Freyer and Schmidt, 2004; Turner et al., 2006). This finding 
possibly explains why L-cysteine alone, or as a constituent of mixtures with different 
excipients, was more stable than the L-cysteine in gums immediately after gum 
preparation. If so, as already mentioned, manufacturing process might have a big role in 
L-cysteine stability.  
Otherwise, at normal temperature and humidity after three months storage, L-cysteine 
salt-containing formulation was less stable than formulation containing base form. High 
temperature and humidity circumstances (75 % relative humidity and 40 °C) effected both 
formulations, and as a result the remaining amount of L-cysteine after three months was 
zero. Again, the study results make it obvious that high temperature and humidity are 
important factors for L-cysteine stability in the final chewing gum formulation. Beside 
those factors, incompatibility between L-cysteine and excipients should also be kept in 
mind. According to the results, it is easy to conclude that for temperature sensitive 
compounds, traditional gum preparation should be avoided because during the 
manufacturing process, the gum base, together with all ingredients, is heated to high 
temperature (40-50 °C).  As mentioned, the low temperature used during the direct 
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compression process, compared with traditional processes, protects thermally unstable 
active substances.  
In general, it was concluded from in vitro stability studies that the formulated chewing 
gum in this study containing L-cysteine should be properly closed during its shelf-life and 
stored under lower temperature and humidity conditions. In addition, for more stable 
product, the preformulation studies should include analysis of the effect of the 
manufacturing method. 
5.2.4 L-cysteine dissolution properties (I, III) 
In vitro dissolution tests in distilled water were carried out first with a pure L-cysteine 
as a free base and as a hydrochloride form to investigate which L-cysteine chemical form 
will be a better candidate for chewing gum formulations (I, Fig.1). The first overall 
finding is that the active substance, both as hydrochloride salt and also as base form, 
dissolves fairly quickly. However, the statistical difference between the two L-cysteine 
forms was highly significant (P < 0.001) and as a result L-cysteine as a base would be a 
better candidate for chewing gum compared to the more water-soluble hydrochloride salt 
form. Changing dissolution fluid from distilled water to artificial saliva with different pH, 
7.4 to mimic normal saliva and 4.7 to mimic lower saliva pH, did not show changes in 
dissolution rates (III, Fig.2).  
Dissolution studies with tablets containing 4 mg of L-cysteine were also in the same 
lines as the above mentioned pure L-cysteine studies (III, Fig. 2). At 5 minutes, 
approximately 83% of the L-cysteine was released and the tablet was completely dissolved 
at 10 minutes. 
The conclusion from the results of the dissolution studies is that L-cysteine might 
release fairly quickly (for about 5 min) also in in vivo studies, which is in this case an 
expected effect, since smoking a cigarette takes about 5 minutes. Furthermore, the 
conclusion that the stability of L-cysteine is not pH dependent is an extremely important 
finding. Thus, L-cysteine products might be effective for users with normal, healthy saliva 
pH, but also for those with lower saliva pH.  
5.3 PAEM model (III) 
The physiologically based simulation model, PAEM, for the prediction of the drug amount 
and the effect on carcinogenic acetaldehyde in the mouth was built using Stella® computer 
programme (III, Fig. 3). The model is based on the in vivo results of six volunteers, and it 
was not validated for a larger population.  
In our groups previous study, it was suggested that tablet formulation containing 
theoretically 5 mg of L-cysteine is sufficient to totally eliminate tobacco smoke 
acetaldehyde from oral cavity (Salaspuro et al., 2006). Due to problems caused by L-
cysteine sensitivity to high pressure induced by compression, the amount found in the 
formulation after preparation was actually 4 mg. Using PAEM model a good correlation 
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was found between acetaldehyde and L-cysteine levels in silico and concentration levels 
measured in vivo (III, Fig. 3, 5). Thus, it might be concluded that the selected 4 mg L-
cysteine amount is enough to drop carcinogenic acetaldehyde levels to below the harmful 
level of 50 μM.  
Further, the model was tested for sensitivity for changes in the lower and higher L-
cysteine amount (III, Fig. 6). Tested amounts were 3 mg and 5 mg. The simulation results 
showed that a drop in the L-cysteine amount from 4 mg to 3 mg might bring an in vivo 
unwanted second acetaldehyde peak between 4 and 5 minutes. In contrast, it was not 
found that an increase in L-cysteine from 4 mg to 5 mg would promote any significant 
changes in acetaldehyde levels. If so, it can be concluded, that a formulation containing 4 
mg of L-cysteine, which was also tested in in vivo studies, is well justified.  
In some cases, local drug delivery to the mouth has been proven to be unsatisfactory 
because of the changing nature of the oral cavity (Seals et al., 1989). Because of that, the 
model was further tested to find out how sensitive acetaldehyde levels are to the changes 
in saliva excretion rate (III, Fig. 7). Simulated results showed that an increase in saliva 
excretion from 2 ml/min to 3 ml/min brought changes in acetaldehyde peaks. As a result, 
an unwanted second peak appears after 3 minutes with a larger AUC than the first peak. 
According to the model, it is therefore suggested that, in this extreme case of high saliva 
excretion, more than 4 mg of L-cysteine is needed to bind tobacco smoke acetaldehyde.  
Since PAEM model is built for L-cysteine, a freely water-soluble compound, it might 
be used to predict the drug amount and local effect in the oral cavity of similar compounds 
or tablet formulations. For example, PAEM model can offer a new possibility in 
eliminating or reducing some other toxic compound using only one formulation containing 
various active compounds. Since the developed model is simple and easy to use, PAEM 
model might be used in the early phase of drug development, when L-cysteine-like 
molecules are chosen for further studies.  This could provide an alternative tool for 
obtaining answers on drug efficacy and safety more rapidly, with more certainty and at 
lower cost (Rajman, 2008). It should be noted that validation of the model requires further 
simulation runs based on larger in vivo data for different formulations or subject groups. 
For example, the model can be used to predict the effect of the drug in different patient 
populations that benefit from the drug (Burman et al., 2005). The model can also be 
extended, for example, to predict drug release during the chewing of a gum. For that, in 
vitro dissolution studies with the European Pharmacopoeia accepted chewing gum 
dissolution apparatus are needed.  
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5.4 In vitro characteristics of MTCA (IV) 
5.4.1 MTCA stability (IV) 
Solid-stage stability 
 
Solid-stage stability results suggested that humidity (60 % RH) as well as higher 
temperature and humidity (45 °C/75 % RH) decreased the remaining amount of 
synthesised MTCA (IV, Fig. 3b). The reason for that might be found in the extra moisture 
which was a source of water solvent for MTCA and thus over time MTCA was dissolved 
and further degraded. If this is the case, in order to obtain reliable results, before any 
experiments the synthesised MTCA should be used within four weeks and properly sealed 
and stored under 25 °C/ 60 % RH.  
 
Solution-state stability 
 
According to the results, MTCA was stable at a neutral pH of 7.4. However, results also 
showed that MTCA is pH-dependent, and degradation into acetaldehyde and cysteine 
possibly occurred. At pH 5.5 after 45 min, the remaining amount was only 32 % of the 
initial amount and 15 % after 24 h (IV, Fig. 4). Since stable MTCA is wanted in different 
parts of the gastrointestinal tract, the result is worrying. After all, unstable MTCA at lower 
pH raises concern that acetaldehyde will release again. To increase the reliability of the 
results, it would be essential to examine whether acetaldehyde is released from MTCA at a 
low pH. If so, acetaldehyde, might have a carcinogenic effect on those parts of the 
gastrointestinal tract where MTCA is deteriorated. Overall, at lower pH, L-cysteine is not 
able to bind effectively and thus to eliminate carcinogenic acetaldehyde.  
5.4.2 MTT cytotoxicity (IV) 
As for L-cysteine in vitro MTT-cytotoxicity of MTCA was examined. MTT-test 
demonstrated that only the highest tested MTCA concentration of 1200 μg/ml had a 
negative effect on mitochondrial activity of the cells (IV, Fig. 5).Thus further, it will be 
essential to investigate in vivo saliva concentrations of MTCA during smoking and 
chewing L-cysteine containing gum. 
5.4.3 Caco-2 permeability studies (IV) 
According to the permeability studies, minimal amounts of MTCA are absorbed from the 
lower parts of gastrointestinal tract. Thus, the risk of systemic effects is minimal. Since 
Caco-2 cells resemble intestinal enterocytes, but tighter junctions and carrier proteins are 
similar to those in the upper gastrointestinal tract, permeability results might indicate that 
minimal amounts of MTCA are also absorbed from the oral cavity. 
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6 Conclusions and future perspectives 
The following conclusions can be drawn from the results: 
 
 According to the results, active ingredient both as a hydrochloride salt and as a 
base, released fairly quickly from the developed chewing gum (I). Since 
cigarette smoking time is a short period (about five minute), fast release of L-
cysteine from the formulations is a desired property. Still, the compressed gum 
requires further evaluation to decrease the “crumbing effect” for better user-
friendly formulation. Crumbing of the gum into small fragments at the 
beginning of chewing is more pronounced for gums prepared by direct 
compression than for chewing gum manufactured by the traditional method.  
 
 The in vivo results showed that carcinogenic acetaldehyde of tobacco smoke 
might be eliminated during five-minute smoking, below mutagenic 
acetaldehyde levels, with all developed L-cysteine chewing gum formulations 
(I). Formulation containing 7.7 mg of L-cysteine was able to eliminate all of 
the acetaldehyde from the oral cavity during smoking.  
 
 It was found that under different temperature and humidity conditions,             
L-cysteine as a pure and as a component of binary mixture with different 
excipients is more stable than L-cysteine hydrochloride (II). However, taking 
together the results from the L-cysteine interactions with tested excipients and 
results from L-cysteine stability in chewing gum, it might be concluded that 
high temperature and humidity are important factors for the stability of the final 
L-cysteine-containing products. Thus, the final product should be well 
protected from high temperature and humidity. Due to better stability at normal 
temperature and humidity in a final formulation, the use of L-cysteine as a base 
form rather than its salt form is well justified. 
 
 The PAEM model developed based on in vitro and in vivo results may be a 
valuable tool for the prediction of drug amount and the local effect of a water-
soluble compound in the mouth, such as L-cysteine is (III). The model shows 
how sensitive acetaldehyde is to changes in L-cysteine amount, as well as 
sensitivity to changes in salivary excretion rate.  
 
 The Caco-2 permeability results showed that there is minimal risk of the locally 
administered L-cysteine being absorbed before binding to acetaldehyde and 
that the risk of local side effects while using these formulations is minimal 
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(IV). The Caco-2 permeability results also indicated that MTCA, the final 
product of reaction between L-cysteine and acetaldehyde, is not absorbed 
locally from the lower parts of gastrointestinal tract, which reduces the risk of 
systemic effects. MTT test showed that both L-cysteine and MTCA are non-
toxic to the Caco-2 cells. Thus, results indicated that the L-cysteine, at the 
concentrations used in this study, seems to be safe in humans.  
 
 Solution-state stability results showed that MTCA stability is pH-dependent, 
and possibly at lower pH (< 5.5) L-cysteine is not able to bind and eliminate 
carcinogenic acetaldehyde (IV). That raises the consideration about L-cysteine 
efficacy in reducing the risk of cancer caused by acetaldehyde at lower pH in 
the gastrointestinal tract. 
 
In conclusion, elimination of tobacco smoking carcinogenic acetaldehyde by                    
L-cysteine containing chewing gum may possibly lead to lower the risk of development of 
upper gastrointestinal tract cancers. With chewing gum prepared by direct compression 
method it would be possible to avoid the high costs associated with traditional chewing 
gum production. Since acetaldehyde is also an agent which possibly increases the 
addictive potential of tobacco, reducing acetaldehyde levels in the mouth may play a 
significant role in fighting against tobacco addiction. Despite encouraging results for both 
hypotheses, more data is required from experimental studies, and the most efficient way to 
protect from smoking damage is still to refrain from smoking altogether. However, it 
should be kept in mind that besides the fact that most smokers want to quit, most attempts 
fail, and smoke contains many carcinogenic compounds. In the future, developed 
computational models can offer a new view in eliminating or reducing not only one toxic 
compound from tobacco smoke, but also many other compounds by using only one 
formulation containing various active compounds. 
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